Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression and association between PRMT5 and MYC in primary medulloblastoma tumors were investigated using publicly available databases.
|
31694585 |
2019 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Critically, G207 delivered to the cerebellum was able to target/treat the highly aggressive MYC-overexpressed group 3 murine medulloblastoma increasing survival vs controls.
|
30918335 |
2019 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
JHU-083 treatment caused decreased growth and increased apoptosis in human MYC-expressing medulloblastoma cell lines.
|
31340195 |
2019 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High MYC mRNA expression and MYC gene amplification in MB have been considered as indicators of poor prognosis.
|
30901604 |
2019 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MK-8628 showed therapeutic efficacy against in vitro and in vivo models of MYC-amplified medulloblastoma by inducing apoptotic cell death and cell cycle arrest.
|
30611741 |
2019 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We find that higher MYC levels are associated with increased EZH2, and pharmacological blockade of EZH2 is a potential therapeutic strategy for aggressive medulloblastoma with elevated MYC.
|
30632221 |
2019 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study highlights B7-H3 as a viable target in MB angiogenesis, and that the expression of miR-29 can inhibit B7-H3 and sensitize MB cells to treatment with MYC-inhibiting drugs.
|
31382461 |
2019 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combined functional genomic and chemical screens identify SETD8 as a therapeutic target in MYC-driven medulloblastoma.
|
30626740 |
2019 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, our data provide insights about the mechanisms underlying BETi effects and the appearance of resistance and support the therapeutic use of combined cell-cycle inhibitors with BETi in MYC-amplified medulloblastoma.
|
31160565 |
2019 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We performed analysis of GABR and MYC expression in MB tumors and used molecular, cell biological, and whole-cell electrophysiology approaches to establish presence of a functional 'druggable' GABA<sub>A</sub>R in group 3 cells.
|
30725256 |
2019 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Most children with medulloblastoma fall within the standard-risk clinical disease group defined by absence of high-risk features (metastatic disease, large-cell/anaplastic histology, and MYC amplification), which includes 50-60% of patients and has a 5-year event-free survival of 75-85%.
|
30392813 |
2018 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Results also demonstrated that the MYC-amplified MB lines showed a higher sensitivity to combined therapies compared to non-MYC-amplified cell lines.
|
29682173 |
2018 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of repair processes and comparison of the mouse tumors with human medulloblastomas (n = 68) and glioblastomas (n = 32) identified chromothripsis as associated with MYC/MYCN gains and with DNA repair deficiencies, pointing towards therapeutic opportunities to target DNA repair defects in tumors with complex genomic rearrangements.
|
30420702 |
2018 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The BET inhibitor JQ1 suppressed MYC expression in a human G3 MB cell line (HD-MB03) and CRISPR-Myc, but not in Retro-Myc MBs.
|
29880921 |
2018 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, combination therapy with S3-NTDi and cisplatin significantly decreased highly aggressive MYC-amplified MB cell growth and induced apoptosis by downregulating STAT3 regulated proliferation and anti-apoptotic gene expression.
|
29280516 |
2018 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In cell lines, SHH MB, which are low-MYC expressing, demonstrated both constitutive and inducible expression of PD-L1 while those in Group 3/4 that expressed high levels of MYC had only inducible expression.
|
29721192 |
2018 |
Medulloblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, the combination treatment significantly prolonged survival as compared to single-agent therapy in orthotopically transplanted human Group 3 MB with MYC amplifications.
|
29511348 |
2018 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Human MYC-amplified (Med8A and D283) and non-amplified (UW228-2 and ONS76) MB cell lines were incubated for 2, 4 or 6 h with increasing doses (0-100 μg/ml) of 5-ALA, and PPIX accumulation was determined by flow cytometry.
|
30445362 |
2018 |
Medulloblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Functional analysis of enriched pathways highlighted cell-cycle progression and protein synthesis as therapeutic targets for MYC-like medulloblastoma.
|
29562177 |
2018 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In line with these findings we show for MYC-amplified medulloblastoma a profound reduction in activity of the oncogenes STAT3 and AKT.
|
28159923 |
2017 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells.
|
28504719 |
2017 |
Medulloblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
TEAD4's co-activator, YAP1, and the downstream targets, MYC and CCND1, were also found to be upregulated in AT/RT when compared to medulloblastoma.
|
27966820 |
2017 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To identify targetable vulnerabilities, we employed inhibitor screening that revealed mTOR inhibitor hypersensitivity in the MYC-overexpressing medulloblastoma cell line, D341.
|
28409891 |
2017 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Historical risk stratification criteria for medulloblastoma rely primarily on clinicopathological variables pertaining to age, presence of metastases, extent of resection, histological subtypes and in some instances individual genetic aberrations such as MYC and MYCN amplification.
|
27040285 |
2016 |
Medulloblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
DiSCoVER analysis predicted that aggressive MYC-driven Group 3 medulloblastoma would be sensitive to cyclin-dependent kinase (CDK) inhibitors.
|
27012813 |
2016 |